Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Overall-survival analysis of ADAURA: osimertinib in resected EGFRm stage IB-IIIA NSCLCПодробнее

Five Year Update on ADAURA Clinical Trial of Tagrisso in EGFR Early Stage NSCLC.Подробнее

Front-line targeted therapy for advanced EGFR-positive diseaseПодробнее

Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC? (BMIC-017)Подробнее

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLCПодробнее

CRSF 07th Masterclass: Osimertinib vs. Decotinib as First-Line Therapy in EGFR Mutated Lung CancerПодробнее

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLCПодробнее

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...Подробнее

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine StrategiesПодробнее

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2Подробнее

Current treatment recommendations and future directions for EGFR-mutant NSCLCПодробнее

FLAURA final analysis: osimertinib for first-line EGFRm NSCLCПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

Phase III Data Support Frontline Osimertinib in EGFR-Mutant Lung CancersПодробнее

Targeted treatment with EGFR TKIs: Front line optionsПодробнее

Updates from ADAURA: continued DFS benefit with osimertinib vs. placeboПодробнее

Copy of Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLCПодробнее

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the rea...Подробнее

Osimertinib for Treatment of EGFR+ Lung CancerПодробнее